REVVITY, INC.
RVTYAPI behind this page
RVTY FY 2025 request
Playground key active
/api/financials?ticker=RVTY&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 2,856,051 | 2,755,026 | +3.7% |
Show Product Lines breakouts |
|||
| Product | 2,389,984 | 2,338,211 | +2.2% |
| Service | 466,067 | 416,815 | +11.8% |
Show Business Segments breakouts |
|||
| Diagnostics [Member] | 1,424,947 | 1,356,425 | +5.1% |
| Diagnostics [Member] · Americas | 505,104 | 477,881 | +5.7% |
| Diagnostics [Member] · Asia | 438,372 | 451,103 | -2.8% |
| Diagnostics [Member] · Europe | 481,471 | 427,441 | +12.6% |
| Diagnostics [Member] · Immunodiagnostics [Member] | 869,908 | 828,627 | +5.0% |
| Diagnostics [Member] · Reportable Segment Revenue [Member] | 1,424,947 | 1,356,425 | +5.1% |
| Diagnostics [Member] · Reproductive health [Member] | 555,039 | 527,798 | +5.2% |
| Life Sciences [Member] | 1,431,104 | 1,398,601 | +2.3% |
| Life Sciences [Member] · Americas | 750,857 | 745,206 | +0.8% |
| Life Sciences [Member] · Asia | 336,740 | 338,222 | -0.4% |
| Life Sciences [Member] · Europe | 343,507 | 315,173 | +9.0% |
| Life Sciences [Member] · Life Sciences Solutions [Member] | 1,194,728 | 1,197,802 | -0.3% |
| Life Sciences [Member] · Reportable Segment Revenue [Member] | 1,431,104 | 1,398,601 | +2.3% |
| Life Sciences [Member] · Software [Member] | 236,376 | 200,799 | +17.7% |
Show Geography breakouts |
|||
| Americas | 1,255,961 | 1,223,087 | +2.7% |
| Asia | 775,112 | 789,325 | -1.8% |
| CN | 425,060 | 450,007 | -5.5% |
| DE | 177,664 | 162,575 | +9.3% |
| Europe | 824,978 | 742,614 | +11.1% |
| GB | 126,849 | 112,883 | +12.4% |
| Other International [Member] | 1,000,204 | 931,705 | +7.4% |
| Total international [Member] | 1,729,777 | 1,657,170 | +4.4% |
| US | 1,126,274 | 1,097,856 | +2.6% |
Show Major goods/service lines [Axis] breakouts |
|||
| Immunodiagnostics [Member] | 869,908 | 828,627 | +5.0% |
| Life Sciences Solutions [Member] | 1,194,728 | 1,197,802 | -0.3% |
| Reproductive health [Member] | 555,039 | 527,798 | +5.2% |
| Software [Member] | 236,376 | 200,799 | +17.7% |
Show Segment Reporting [Axis] breakouts |
|||
| Reportable Segment Revenue [Member] | 2,856,051 | 2,755,026 | +3.7% |
| Cost of Revenue (FY) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 1,117,132 | 1,041,749 | +7.2% |
| Service | 174,554 | 175,618 | -0.6% |
| Selling, General & Administrative | 991,890 | 994,074 | -0.2% |
| Research & Development | 215,840 | 196,844 | +9.7% |
| Operating Income | 356,635 | 346,741 | +2.9% |
| Interest And Other Expense Net | 88,358 | 30,615 | +188.6% |
| Income Before Taxes | 268,277 | 316,126 | -15.1% |
| Income Tax Expense (Benefit) | 28,394 | 33,055 | -14.1% |
| Income Loss From Continuing Operations | 239,883 | 283,071 | -15.3% |
| Income Loss From Discontinued Operations Net Of Tax | 1,318 | -12,686 | +110.4% |
| Net Income | 241,201 | 270,385 | -10.8% |
Show Equity Components breakouts |
|||
| Retained Earnings | 241,201 | 270,385 | -10.8% |
| Income Loss From Continuing Operations Per Basic Share | 2.06 | 2.31 | -10.8% |
| Income Loss From Discontinued Operations Net Of Tax Per Basic Share | 0.01 | -0.1 | +110.0% |
| EPS (Basic) | 2.07 | 2.21 | -6.3% |
| Income Loss From Continuing Operations Per Diluted Share | 2.06 | 2.3 | -10.4% |
| Income Loss From Discontinued Operations Net Of Tax Per Diluted Share | 0.01 | -0.1 | +110.0% |
| EPS (Diluted) | 2.07 | 2.2 | -5.9% |
| Non-Operating Income (Expense) | -88,358 | -30,615 | -188.6% |
| Interest Expense | 92,185 | 96,278 | -4.3% |
| Interest Income | -31,103 | -73,190 | +57.5% |
| Comprehensive Income | 415,171 | 150,972 | +175.0% |
| Wtd Avg Shares (Basic) | 116,542 | 122,756 | -5.1% |
| Wtd Avg Shares (Diluted) | 116,595 | 122,822 | -5.1% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 919,860 | 1,163,396 | -20.9% |
| Accounts Receivable | 744,671 | 632,400 | +17.8% |
| Inventory | 379,497 | 367,587 | +3.2% |
| Other Assets Current | 195,719 | 186,225 | +5.1% |
| Total Current Assets | 2,239,747 | 2,349,608 | -4.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 479,249 | 482,217 | -0.6% |
| Operating Lease Right-of-Use Assets | 165,439 | 167,716 | -1.4% |
| Goodwill | 6,613,493 | 6,463,619 | +2.3% |
Show Business Segments breakouts |
|||
| Diagnostics [Member] | 1,868,531 | 1,922,152 | -2.8% |
| Life Sciences [Member] | 4,744,962 | 4,541,467 | +4.5% |
| Other Non-Current Assets | 323,480 | 288,397 | +12.2% |
| Total Assets | 12,168,411 | 12,392,478 | -1.8% |
| Intangible Assets | 2,347,003 | 2,640,921 | -11.1% |
Show Finite and Indefinite Lived Intangible Assets by Major Class [Axis] breakouts |
|||
| Core Technology [Member] | 703,600 | 826,299 | -14.8% |
| Customer Relationships | 1,586,754 | 1,749,034 | -9.3% |
| Licensing Agreements | 7,712 | 9,309 | -17.2% |
| Patents | 1,068 | 1,515 | -29.5% |
| Trade Names And Trademarks [Member] | 47,869 | 54,764 | -12.6% |
| Marketable Securities (Non-Current) | 27,956 | 27,413 | +2.0% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 2,347,003 | 2,640,921 | -11.1% |
| Current Liabilities | |||
| Other Long Term Debt Current | 588,828 | 242 | +243217.4% |
| Accounts Payable | 185,464 | 167,463 | +10.7% |
| Accrued Liabilities | 556,954 | 485,395 | +14.7% |
| Total Current Liabilities | 1,331,246 | 653,100 | +103.8% |
| Deferred Revenue | 160,194 | 140,212 | +14.3% |
| Current Portion of Long-Term Debt | 588,828 | 242 | +243217.4% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · 1.875 Percent Ten Year Senior Unsecured Notes [Member] | 588,828 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 2,631,236 | 3,150,476 | -16.5% |
| Other Non-Current Liabilities | 807,461 | 770,523 | +4.8% |
| Operating Lease Liabilities | 148,108 | 151,505 | -2.2% |
| Total Liabilities | 4,918,051 | 4,725,604 | +4.1% |
| Long-Term Debt (Q) | — | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 2,631,236 | 3,150,476 | -16.5% |
| Fair Value Inputs Level2 · 1.900% Senior Unsecured Notes due 2028 | 498,061 | 497,392 | +0.1% |
| Fair Value Inputs Level2 · 2.250% Senior Unsecured Notes due in 2031 | 496,440 | 495,876 | +0.1% |
| Fair Value Inputs Level2 · 2.55 Percent Senior Unsecured Notes due in 2031 | 397,973 | 397,618 | +0.1% |
| Fair Value Inputs Level2 · 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | 845,596 | 844,542 | +0.1% |
| Fair Value Inputs Level2 · 3.625 Percent Senior Unsecured Notes due in 2051 | 396,023 | 395,937 | 0.0% |
| Fair Value Inputs Level2 · Senior Unsecured Notes | 3,222.9 | 3,151.5 | +2.3% |
Show Debt Instrument breakouts |
|||
| Line of Credit, Maturing January 7, 2030 | 2,857 | — | — |
| Stockholders' Equity | |||
| Common Stock | 112,281 | 120,646 | -6.9% |
| Additional Paid In Capital Common Stock | 1,305,900 | 2,097,110 | -37.7% |
| Retained Earnings | 6,054,314 | 5,845,223 | +3.6% |
| Accumulated Other Comprehensive Income | -222,135 | -396,105 | +43.9% |
| Total Stockholders' Equity | 7,250,360 | 7,666,874 | -5.4% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -222,135 | -396,105 | +43.9% |
| Additional Paid In Capital | 1,305,900 | 2,097,110 | -37.7% |
| Common Stock | 112,281 | 120,646 | -6.9% |
| Retained Earnings | 6,054,314 | 5,845,223 | +3.6% |
| Total Liabilities & Equity | 12,168,411 | 12,392,478 | -1.8% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Restructuring And Other Costs Net | 55,932 | 17,454 | +220.5% |
| Depreciation & Amortization | 405,340 | 427,849 | -5.3% |
| Stock-Based Compensation | 22,847 | 37,809 | -39.6% |
| Pension And Other Postretirement Benefit Expense | 3,639 | 9,381 | -61.2% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -1,400 | -1,869 | +25.1% |
| Deferred Income Taxes | -61,483 | -102,232 | +39.9% |
| Contingencies And Non Cash Tax Matters | -86 | -8,073 | +98.9% |
| Amortization Of Financing Costs And Discounts | 4,552 | 6,073 | -25.0% |
| Asset Impairment Charges | 4,784 | 22,814 | -79.0% |
| Change In Fair Value Of Investments | 11,456 | -7,958 | +244.0% |
| Foreign Currency Transaction Gain Loss Unrealized | 273 | -1,059 | +125.8% |
| Change in Accounts Receivable | -101,023 | -15,969 | -532.6% |
| Change in Inventory | 14,782 | 45,086 | -67.2% |
| Change in Accounts Payable | 7,345 | -26,025 | +128.2% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -17,885 | -21,397 | +16.4% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 588,956 | 664,955 | -11.4% |
| Cash Provided By Used In Operating Activities Discontinued Operations | -6,023 | -36,656 | +83.6% |
| Net Cash from Operations | 582,933 | 628,299 | -7.2% |
| Investing Activities | |||
| Capital Expenditures | -73,522 | -86,648 | +15.1% |
| Purchases Of Investments And Notes Receivables | -385 | -6,587 | +94.2% |
| Proceeds From Divestiture Of Businesses | 304 | 2,500 | -87.8% |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -73,603 | 619,265 | -111.9% |
| Cash Provided By Used In Investing Activities Discontinued Operations | 56,250 | 156,897 | -64.1% |
| Net Cash from Investing | -17,353 | 776,162 | -102.2% |
| Financing Activities | |||
| Debt Issuance Costs | -2,474 | — | — |
| Proceeds From Repayments Of Other Debt | -521 | -11,593 | +95.5% |
| Payments For Acquisition Related Contingent Consideration | -3,838 | -8,832 | +56.5% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 2,925 | 7,701 | -62.0% |
| Share Repurchases | -820,815 | -369,578 | -122.1% |
| Payments Of Dividends Common Stock | -32,800 | -34,454 | +4.8% |
| Net Cash from Financing | -857,523 | -1,128,235 | +24.0% |
| Supplemental | |||
| Interest Paid | 86,195 | 91,092 | -5.4% |
| Income Taxes Paid | 131,350 | — | — |
| Other Cash Flow | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 921,030 | 1,164,452 | -20.9% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 48,521 | -26,147 | +285.6% |
| Net Change in Cash | -243,422 | 250,079 | -197.3% |
| Restricted Cash Current | 6 | 1,056 | -99.4% |
| Restricted Cash Noncurrent | 1,164 | — | — |
Values in thousands USD. Source: SEC EDGAR 10-K filing.